Great studies often lead to hastened reviews by the FDA and so will be the case for Xarelto (rivaroxaban) a new blood thinner from a new family (direct factor 10A inhibitors). The FDA granted a Priority Review for the use (indication) of preventing a second cardiovascular (heart and blood vessel) event in people with Acute Coronary Sundromes (ACS).
We need some additional information. ACS includes Unstable Angina, Non ST elevation Myocardial Infarction (NSTEMI) and what we all usually think of as a heart attack or ST elevation myocardial infarction or MI.
This priority review was based on a large study called the ATLAS ACS 2-TIMI 51 study. This has already been reported elsewhere on this web site, but also rest assured that the study in detailed in the current Essential Guide to Prescription Drugs, knowing Xarelto. Visit Amazon for more or click here:www.amazon.com/dp/B007AKIENI
The original presentation of the ATLAS ACS study was last November at the American Heart Association meeting. This editor has noted many times subsequently that the data from the study was very impressive and that while the 2.5 mg dose would have to be given twice a day, Xarelto would be a positive game changer in helping prevent a second heart attack.